Clinical and Experimental Allergy最新文献

{"title":"Complementary Analysis of Local and Systemic Effects of Dupilumab in Paediatric AD Using Tape Strips and Serum.","authors":"Lisa P van der Rijst, Edward F Knol, Nicolaas P A Zuithoff, Constance F den Hartog Jager, Femke van Wijk, Marjolein S de Bruin-Weller, Marlies de Graaf","doi":"10.1111/cea.70082","DOIUrl":"https://doi.org/10.1111/cea.70082","url":null,"abstract":"<p><strong>Objective: </strong>This study investigates local and systemic immune-related proteins in tape strips and serum of paediatric atopic dermatitis (AD) patients treated with dupilumab, and explores their correlation with clinical severity.</p><p><strong>Methods: </strong>Twenty paediatric AD patients (< 18 years) starting dupilumab treatment were included. Serum samples and tape strips from lesional and non-lesional skin were collected at baseline, 4 and 16 weeks of treatment. Fifteen pre-specified proteins were measured at each visit by Luminex multiplex immunoassay. Clinical severity outcome measures included the Eczema Area and Severity Index (EASI) and Numeric Rating Scale (NRS) itch. Statistical analyses included Wilcoxon signed-rank tests and Spearman correlations.</p><p><strong>Results: </strong>Along with clinical improvement, 16 weeks of dupilumab treatment resulted in a rapid and significant reduction in the disease-associated mediators PARC/CCL18 and TARC/CCL17 in both tape-stripped skin and serum. While the cytokine and chemokine profiles differed between the sampling methods, both effectively captured immunological changes associated with dupilumab treatment. Tape strips demonstrated significant reductions in innate pro-inflammatory cytokines (IL-8/CXCL8, IL-18), the T cell-recruiting chemokine CTACK/CCL27, the Type 1 immune mediator CXCL10, and tissue repair and remodelling proteins (periostin, MMP-1) in response to treatment, but were less sensitive in detecting T cell-derived cytokines (IL-4, IL-13). In both skin and serum, several proteins were significantly correlated with AD severity, as measured by EASI and NRS itch, with PARC/CCL18 emerging as the strongest correlated protein.</p><p><strong>Conclusion: </strong>Our findings provide insight into the distinct local and systemic proteomic changes in response to dupilumab treatment in paediatric AD patients. These findings underscore the complementary roles of tape strips and serum in profiling immune and epidermal barrier proteins, highlighting the utility of minimally invasive tape stripping for monitoring proteomic responses to targeted therapies in paediatric AD.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Study of Fractional Exhaled Nitric Oxide (FeNO) and Spirometric Indices in Trainee Bakers and Confectioners.","authors":"Gina-Maria Klaut, Ludwig Frei-Stuber, Stefan Karrasch, Susanne Kutzora, Jonas Huss, Doris Gerstner, Dennis Nowak, Caroline Quartucci","doi":"10.1111/cea.70076","DOIUrl":"https://doi.org/10.1111/cea.70076","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143980755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Walnut Allergy in Children: A Diagnostic Test Accuracy Study.","authors":"Mattia Giovannini, Camilla Fazi, Martina Tesi, Giulia Liccioli, Lucrezia Sarti, Simona Barni, Leonardo Tomei, Benedetta Pessina, Claudia Valleriani, Robert Boyle, Riccardo Pertile, Francesca Mori","doi":"10.1111/cea.70078","DOIUrl":"https://doi.org/10.1111/cea.70078","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144074962","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis and Treatment of Atopic Dermatitis: Lessons From China.","authors":"Xu Yao, Wei Li","doi":"10.1111/cea.14631","DOIUrl":"https://doi.org/10.1111/cea.14631","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143974433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interaction Between Lifestyle, Immunity and Gut Microbiota in Milk Allergy Children.","authors":"Kiwako Yamamoto-Hanada, Eiryo Kawakami, Miori Sato, Makoto Irahara, Kenji Toyokuni, Erika Hiraide-Kotaki, Naomi Harima-Mizusawa, Norihiro Kubota, Hideaki Morita, Kenji Matsumoto, Tatsuki Fukuie, Yukihiro Ohya","doi":"10.1111/cea.70080","DOIUrl":"https://doi.org/10.1111/cea.70080","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143954949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of COVID-19 on Patients With Bradykinin-Mediated Angioedema in the ITACA Cohort.","authors":"Riccardo Senter, Andrea Zanichelli, Agolini Stefano, Francesco Arcoleo, Donatella Bignardi, Paolo Borrelli, Chiara Cogliati, Caterina Colangelo, Tiziana De Pasquale, Stefano Del Giacco, Davide Firinu, Antonio Gidaro, Mariangela Lo Pizzo, Roberta Parente, Francesca Perego, Angelica Petraroli, Valentina Popescu Janu, Stefano Pucci, Paolina Quattrocchi, Irene Ridolfi, Oliviero Rossi, Federica Ruin, Giuseppe Spadaro, Paola Triggianese, Alessandra Zoli, Massimo Triggiani, Mauro Cancian","doi":"10.1111/cea.70079","DOIUrl":"https://doi.org/10.1111/cea.70079","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rising Use and Need for Oral Food Challenges in Adolescents and Young Adults: Implications for Allergy Management.","authors":"Marei Omori, Kiwako Yamamoto-Hanada, Daisuke Harama, Sayaka Hamaguchi, Kouhei Hagino, Daichi Suzuki, Kotaro Umezawa, Fumi Ishikawa, Seiko Hirai, Kenji Toyokuni, Tatsuki Fukuie, Yukihiro Ohya","doi":"10.1111/cea.70073","DOIUrl":"https://doi.org/10.1111/cea.70073","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploratory Safety Evaluation of Dupilumab Combined With Subcutaneous Immunotherapy in House Dust Mite-Sensitised Patients With Atopic Dermatitis: A Retrospective Case Series From Northern China.","authors":"Xu Li, Yanfei Li, Junjing Zhang, Shuang Wu, Liya Ai, Xin Tong, Change Fan, Huijiao Cai, Jingxue Guo, Tingting Gao, Peize Liu, Na Liu, Peng Jin, Lili Zhi","doi":"10.1111/cea.70077","DOIUrl":"https://doi.org/10.1111/cea.70077","url":null,"abstract":"<p><p>Patients with atopic dermatitis (AD) are frequently sensitised to house dust mites (HDM). While Dupilumab is effective, the role of subcutaneous immunotherapy (SCIT) remains unclear. This study evaluated the safety and clinical outcomes of combined Dupilumab and SCIT in HDM-sensitised AD patients. In this retrospective study, 47 adults with HDM-sensitised AD received concurrent Dupilumab and HDM-SCIT for 48 weeks. Eczema Area and Severity Index (EASI) scores, total and HDM-specific IgE levels were monitored. Safety was assessed by adverse events related to SCIT and Dupilumab. EASI scores improved significantly from baseline (28.4 ± 6.9) to Week 12 (14.8 ± 4.5), Week 24 (12.7 ± 4.3) and Week 48 (5.2 ± 2.8). HDM-specific IgE (d1, d2) and total IgE decreased by Week 48 (p < 0.05). SCIT-related local and systemic reactions declined over time. Dupilumab-related conjunctivitis, head and neck dermatitis, and upper respiratory tract infections were transient and reduced during follow-up. The combination of Dupilumab and SCIT was well tolerated and associated with clinical improvement and IgE reduction in HDM-sensitised AD patients. These findings support further investigation in prospective controlled trials.</p>","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143955947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spectrum and Impact of Reported Side Effects of Omalizumab in Patients With Chronic Urticaria: A Long-Term Multicentre Real-World Study","authors":"Reineke Soegiharto,&nbsp;Esther Van der Wind,&nbsp;Mehran Alizadeh Aghdam,&nbsp;Jennifer A. Sørensen,&nbsp;Esmee Van Lindonk,&nbsp;Ferhan Bulut Demir,&nbsp;Nasser Mohammad Porras,&nbsp;Yoshimi Matsuo,&nbsp;Lea Kiefer,&nbsp;André C. Knulst,&nbsp;Marcus Maurer,&nbsp;Carla Ritchie,&nbsp;Michael Rudenko,&nbsp;Emek Kocatürk,&nbsp;Roberta Fachini Jardim Criado,&nbsp;Stamatis Gregoriou,&nbsp;Tatjana Bobylev,&nbsp;Andreas Kleinheinz,&nbsp;Shunsuke Takahagi,&nbsp;Michihiro Hide,&nbsp;Ana M. Giménez-Arnau,&nbsp;Andaç Salman,&nbsp;Rabia Oztas Kara,&nbsp;Bahar Sevimli Dikicier,&nbsp;Martijn B. A. Van Doorn,&nbsp;Simon F. Thomsen,&nbsp;Juul M. P. A. Van den Reek,&nbsp;Heike Röckmann","doi":"10.1111/cea.70067","DOIUrl":"10.1111/cea.70067","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Chronic urticaria (CU) treatment with omalizumab is considered safe in short-term studies. Large real-world studies focusing on the long-term safety of omalizumab and associated factors are lacking. We aimed to investigate the spectrum of reported side effects in omalizumab-treated CU patients in a large long-term daily practice cohort.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A multinational multicentre retrospective study was conducted at 14 specialised urticaria centres (UCAREs), including all CU patients ever treated with omalizumab until centre-specific data lock. The prevalence of patient-reported side effects was assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;A total of 1859 patients were included, of which 32.9% (&lt;i&gt;n&lt;/i&gt; = 612) reported side effects during omalizumab treatment with a wide range across centres (0%–75.5%). Fatigue (15.8%, &lt;i&gt;n&lt;/i&gt; = 293), headache (11.6%, &lt;i&gt;n&lt;/i&gt; = 215) and flu-like symptoms (9.3%, &lt;i&gt;n&lt;/i&gt; = 172) were most common. No events suggestive of anaphylaxis and no new notably prevalent side effects were reported. Hair loss was reported by 2.9% (&lt;i&gt;n&lt;/i&gt; = 53/1859) of patients, leading to treatment adjustment in 21.1% (&lt;i&gt;n&lt;/i&gt; = 8/38 with sufficient data). Patients who reported side effects were more often female (78.3% vs. 68.6%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), had worse disease control prior to omalizumab (Urticaria Control Test, UCT, 4.0 vs. 6.0, &lt;i&gt;p&lt;/i&gt; &lt; 0.001), and lower fast response (Weekly Urticaria Activity Score, UAS7, &lt; 7 or UCT &gt; 11 within 4 weeks, 42.6% vs. 59.5%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) and complete/good response rates (UAS7 &lt; 7 or UCT &gt; 11 at end of treatment, 72.3% vs. 84.4%, &lt;i&gt;p&lt;/i&gt; &lt; 0.001) compared to patients without side effects. While only 2.4% (&lt;i&gt;n&lt;/i&gt; = 44/1859) of patients discontinued treatment due to side effects, 5.5% (&lt;i&gt;n&lt;/i&gt; = 100/1859) and 12.8% (&lt;i&gt;n&lt;/i&gt; = 238/1859) of patients reporting side effects with insufficient (UAS7 ≥ 7 or UCT 3–11 at end of treatment) and complete/good response, respectively, remained on omalizumab.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusions&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The safety and tolerability of omalizumab was confirmed. Notably, the wide variation in reported side effects across centres suggests that differences in awareness influence reporting. Hair loss was more prevalent than described before, warranting extra attention. Side effects were more often reported in patients whose characteristics suggest reduced effectiveness of omalizumab, possibly related to a negative association with omalizumab and suggestin","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":"55 6","pages":"481-492"},"PeriodicalIF":6.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cea.70067","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Water hardness and atopic dermatitis in the first year of life in the New Hampshire Birth Cohort Study.","authors":"","doi":"10.1111/cea.70070","DOIUrl":"https://doi.org/10.1111/cea.70070","url":null,"abstract":"","PeriodicalId":10207,"journal":{"name":"Clinical and Experimental Allergy","volume":" ","pages":""},"PeriodicalIF":6.3,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}